Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-870,893 + cisplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CP-870,893 + cisplatin + pemetrexed is a combination therapy consisting of a CD40 agonist monoclonal antibody (CP-870,893) and two chemotherapy agents (cisplatin and pemetrexed). CP-870,893 activates antigen-presenting cells, triggers inflammatory cytokine release, and enhances antitumor cellular immunity. When combined with chemotherapy, it may facilitate tumor antigen release, potentially enhancing the overall antitumor effect.
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on CP-870,893 + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP-870,893 + cisplatin + pemetrexed.